{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:36:03Z","timestamp":1794072963543,"version":"4.8.0"},"reference-count":69,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Advances in the development of novel treatment options for hemophilia A are prevalent. However, the anti\u2013factor VIII (FVIII) neutralizing antibody (inhibitor) response to existing FVIII products remains a major treatment challenge. Although some novel products are designed to function in the presence of inhibitors, they do not specific address the immunogenicity risk or mechanistic causes of inhibitor development, which remain unclear. Furthermore, most preclinical studies supporting clinical gene therapy programs have reported immunogenicity signals in animal models, especially at higher vector doses and sometimes using multiple vector designs. In these settings, immunogenicity risk factor determination, comparative immunogenicity of competing vector designs, and the potential for obtaining meaningful prognostic data remain relatively unexplored. Additionally, there remains the opportunity to investigate clinical gene therapy as an alternative to standard immune tolerance induction therapy. The current study was designed to address these issues through longitudinal dose-response evaluation of 4 adeno-associated viral (AAV) vector candidates encoding 2 different FVIII transgenes in a murine model of hemophilia A. Plasma FVIII activity and anti-FVIII antibody data were used to generate a pharmacokinetic model that (1) identifies initial AAV-FVIII product expression kinetics as the dominant risk factor for inhibitor development, (2) predicts a therapeutic window where immune tolerance is achieved, and (3) demonstrates evidence of gene therapy\u2013based immune tolerance induction. Although there are known limitations to the predictive value of preclinical immunogenicity testing, these studies can uncover or support the development of design principles that can guide the development of safe and effective genetic medicines.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021006359","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T18:08:38Z","timestamp":1647281318000},"page":"2628-2645","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacokinetic analysis identifies a factor VIII immunogenicity threshold after AAV gene therapy in hemophilia A mice"],"prefix":"10.1182","volume":"6","author":[{"given":"Taran S.","family":"Lundgren","sequence":"first","affiliation":[{"name":"Graduate Program in Molecular and Systems Pharmacology, Laney Graduate School, Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Denning","sequence":"additional","affiliation":[{"name":"Expression Therapeutics, Inc., Tucker, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1130-9551","authenticated-orcid":false,"given":"Sean R.","family":"Stowell","sequence":"additional","affiliation":[{"name":"Joint Program in Transfusion Medicine, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Trent","family":"Spencer","sequence":"additional","affiliation":[{"name":"Expression Therapeutics, Inc., Tucker, GA;"},{"name":"Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5662-0060","authenticated-orcid":false,"given":"Christopher B.","family":"Doering","sequence":"additional","affiliation":[{"name":"Expression Therapeutics, Inc., Tucker, GA;"},{"name":"Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"issue":"1","key":"2022042215221959900_B1","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/ajh.26018","article-title":"2021 clinical trials update: innovations in hemophilia therapy","volume":"96","author":"Croteau","year":"2021","journal-title":"Am J Hematol."},{"issue":"10274","key":"2022042215221959900_B2","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0140-6736(20)32722-7","article-title":"The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing","volume":"397","author":"Mancuso","year":"2021","journal-title":"Lancet."},{"issue":"2","key":"2022042215221959900_B3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in\u00a0vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol Ther."},{"key":"2022042215221959900_B4","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.omtm.2018.12.007","article-title":"Protein-engineered coagulation factors for hemophilia gene therapy","volume":"12","author":"Samelson-Jones","year":"2018","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"R1","key":"2022042215221959900_B5","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1093\/hmg\/ddz157","article-title":"Advances and challenges for hemophilia gene therapy","volume":"28","author":"Batty","year":"2019","journal-title":"Hum Mol Genet."},{"issue":"5","key":"2022042215221959900_B6","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/blood-2018-07-820720","article-title":"Update on clinical gene therapy for hemophilia","volume":"133","author":"Perrin","year":"2019","journal-title":"Blood."},{"issue":"4","key":"2022042215221959900_B7","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ymthe.2019.11.006","article-title":"A molecular revolution in the treatment of hemophilia","volume":"28","author":"Butterfield","year":"2020","journal-title":"Mol Ther."},{"issue":"3","key":"2022042215221959900_B8","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2003-11-3891","article-title":"Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope","volume":"104","author":"Parker","year":"2004","journal-title":"Blood."},{"issue":"10","key":"2022042215221959900_B9","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1089\/hum.2018.137","article-title":"Preclinical development of a hematopoietic stem and progenitor cell bioengineered factor VIII lentiviral vector gene therapy for hemophilia A","volume":"29","author":"Doering","year":"2018","journal-title":"Hum Gene Ther."},{"key":"2022042215221959900_B10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.omtm.2021.11.005","article-title":"Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia A","volume":"24","author":"Elkouby","year":"2021","journal-title":"Mol Ther Methods Clin Dev."},{"key":"2022042215221959900_B11","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.omtm.2019.03.006","article-title":"The impact of pre-existing immunity on the non-clinical pharmacodynamics of AAV5-based gene therapy","volume":"13","author":"Long","year":"2019","journal-title":"Mol\u00a0Ther Methods Clin Dev."},{"issue":"2","key":"2022042215221959900_B12","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ymthe.2017.12.009","article-title":"Gene therapy with BMN 270 results in therapeutic levels of FVIII in mice and primates and normalization of bleeding in hemophilic mice","volume":"26","author":"Bunting","year":"2018","journal-title":"Mol Ther."},{"issue":"17","key":"2022042215221959900_B13","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","article-title":"Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant","volume":"121","author":"McIntosh","year":"2013","journal-title":"Blood."},{"issue":"12","key":"2022042215221959900_B14","first-page":"1364","article-title":"Optimized adeno-associated viral-mediated human factor VIII gene therapy in cynomolgus macaques","volume":"29","author":"Greig","year":"2018","journal-title":"Hum\u00a0Gene Ther."},{"issue":"5","key":"2022042215221959900_B15","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1089\/hum.2016.128","article-title":"Characterization of adeno-associated viral vector-mediated human factor VIII gene therapy in hemophilia A\u00a0mice","volume":"28","author":"Greig","year":"2017","journal-title":"Hum Gene Ther."},{"issue":"7","key":"2022042215221959900_B16","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/jth.14804","article-title":"FVIII activity following FVIII protein infusion or FVIII gene transfer predicts the bleeding risk in hemophilia A rats","volume":"18","author":"L\u00f6vgren","year":"2020","journal-title":"J Thromb Haemost."},{"key":"2022042215221959900_B17","doi-asserted-by":"crossref","first-page":"16064","DOI":"10.1038\/mtm.2016.64","article-title":"Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice","volume":"3","author":"Lange","year":"2016","journal-title":"Mol Ther Methods Clin Dev."},{"key":"2022042215221959900_B18","doi-asserted-by":"crossref","first-page":"14036","DOI":"10.1038\/mtm.2014.36","article-title":"Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery","volume":"1","author":"Brown","year":"2014","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"1","key":"2022042215221959900_B19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2005-12-5115","article-title":"Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood."},{"issue":"1","key":"2022042215221959900_B20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjh.16377","article-title":"Advances in knowledge of inhibitor formation in severe haemophilia A","volume":"189","author":"Cormier","year":"2020","journal-title":"Br J Haematol."},{"key":"2022042215221959900_B21","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.3389\/fimmu.2019.02991","article-title":"Tolerating factor VIII: recent progress","volume":"10","author":"Lacroix-Desmazes","year":"2020","journal-title":"Front Immunol."},{"issue":"10","key":"2022042215221959900_B22","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1182\/blood-2005-03-1182","article-title":"High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors","volume":"106","author":"Hausl","year":"2005","journal-title":"Blood."},{"key":"2022042215221959900_B23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.omtm.2018.01.004","article-title":"Target-cell-directed bioengineering approaches for gene therapy of hemophilia A","volume":"9","author":"Brown","year":"2018","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"27","key":"2022042215221959900_B24","doi-asserted-by":"crossref","first-page":"24451","DOI":"10.1074\/jbc.M111.238758","article-title":"Enhanced biosynthesis of coagulation factor VIII through diminished engagement of the unfolded protein response","volume":"286","author":"Brown","year":"2011","journal-title":"J Biol Chem."},{"issue":"1","key":"2022042215221959900_B25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nbt.3677","article-title":"Enhancing the pharmaceutical properties of protein drugs by ancestral sequence reconstruction","volume":"35","author":"Zakas","year":"2017","journal-title":"Nat Biotechnol."},{"key":"2022042215221959900_B26","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.omtm.2020.10.013","article-title":"Minimal essential human factor VIII alterations enhance secretion and gene therapy efficiency","volume":"19","author":"Cao","year":"2020","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"1","key":"2022042215221959900_B27","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/jth.13543","article-title":"Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A","volume":"15","author":"Nguyen","year":"2017","journal-title":"J Thromb Haemost."},{"issue":"21","key":"2022042215221959900_B28","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2012-10-464164","article-title":"Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype","volume":"121","author":"Siner","year":"2013","journal-title":"Blood."},{"issue":"4","key":"2022042215221959900_B29","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/gt.2012.67","article-title":"Comparison of gene transfer to the murine liver following intraperitoneal and intraportal delivery of hepatotropic AAV pseudo-serotypes","volume":"20","author":"Dane","year":"2013","journal-title":"Gene Ther."},{"issue":"4","key":"2022042215221959900_B30","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1089\/hum.2016.172","article-title":"Impact of AAV capsid-specific T-cell responses on design and outcome of clinical gene transfer trials with recombinant adeno-associated viral vectors: an evolving controversy","volume":"28","author":"Ertl","year":"2017","journal-title":"Hum Gene Ther."},{"issue":"1","key":"2022042215221959900_B31","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1146\/annurev-virology-101416-041936","article-title":"Overcoming the host immune response to adeno-associated virus gene delivery vectors: the race between clearance, tolerance, neutralization, and escape","volume":"4","author":"Mingozzi","year":"2017","journal-title":"Annu Rev Virol."},{"key":"2022042215221959900_B32","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.omtm.2020.03.007","article-title":"Site-directed mutagenesis improves the transduction efficiency of capsid library-derived recombinant AAV vectors","volume":"17","author":"Ran","year":"2020","journal-title":"Mol\u00a0Ther Methods Clin Dev."},{"key":"2022042215221959900_B33","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.addr.2021.01.017","article-title":"Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic\/pharmacodynamic (PK\/PD) models","volume":"170","author":"Chowdhury","year":"2021","journal-title":"Adv Drug Deliv Rev."},{"issue":"7","key":"2022042215221959900_B34","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/gt.2016.26","article-title":"Effects of transgene expression level per cell in mice livers on induction of transgene-specific immune responses after hydrodynamic gene transfer","volume":"23","author":"Yin","year":"2016","journal-title":"Gene Ther."},{"key":"2022042215221959900_B35","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.omtm.2020.05.033","article-title":"Experimental variables that affect human hepatocyte AAV transduction in liver chimeric mice","volume":"18","author":"Zou","year":"2020","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"8","key":"2022042215221959900_B36","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.ymthe.2017.07.007","article-title":"The pharmacology of gene therapy","volume":"25","author":"Yl\u00e4-Herttuala","year":"2017","journal-title":"Mol Ther."},{"issue":"7","key":"2022042215221959900_B37","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/mt.2009.35","article-title":"Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A","volume":"17","author":"Doering","year":"2009","journal-title":"Mol Ther."},{"key":"2022042215221959900_B38","article-title":"Determining the minimally effective dose of a clinical candidate adeno-associated virus vector in a mouse model of hemophilia A [published online ahead of print 8 December 2021]","author":"Greig","journal-title":"Hum Gene Ther."},{"issue":"3","key":"2022042215221959900_B39","doi-asserted-by":"crossref","first-page":"e0151800","DOI":"10.1371\/journal.pone.0151800","article-title":"Successful phenotype improvement following gene therapy for severe hemophilia A in privately owned dogs","volume":"11","author":"Callan","year":"2016","journal-title":"PLoS One."},{"key":"2022042215221959900_B40","doi-asserted-by":"crossref","first-page":"15056","DOI":"10.1038\/mtm.2015.56","article-title":"Effects of FVIII immunity on hepatocyte and hematopoietic stem cell-directed gene therapy of murine hemophilia A","volume":"3","author":"Lytle","year":"2016","journal-title":"Mol Ther Methods Clin Dev."},{"key":"2022042215221959900_B41","doi-asserted-by":"crossref","first-page":"16063","DOI":"10.1038\/mtm.2016.63","article-title":"Potential for cellular stress response to hepatic factor VIII expression from AAV vector","volume":"3","author":"Zolotukhin","year":"2016","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"5","key":"2022042215221959900_B42","doi-asserted-by":"crossref","first-page":"e37671","DOI":"10.1371\/journal.pone.0037671","article-title":"Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy","volume":"7","author":"Sack","year":"2012","journal-title":"PLoS One."},{"issue":"12","key":"2022042215221959900_B43","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/gt.2011.200","article-title":"AAV-based neonatal gene therapy for hemophilia A: long-term correction and avoidance of immune responses in mice","volume":"19","author":"Hu","year":"2012","journal-title":"Gene Ther."},{"issue":"3","key":"2022042215221959900_B44","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/mt.2010.240","article-title":"Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors","volume":"19","author":"Sabatino","year":"2011","journal-title":"Mol Ther."},{"issue":"1","key":"2022042215221959900_B45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nat Biotechnol."},{"issue":"11","key":"2022042215221959900_B46","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/jgm.1391","article-title":"Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice","volume":"11","author":"Ishiwata","year":"2009","journal-title":"J Gene Med."},{"issue":"4","key":"2022042215221959900_B47","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1089\/hum.2006.17.427","article-title":"Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice","volume":"17","author":"Sarkar","year":"2006","journal-title":"Hum Gene Ther."},{"issue":"5","key":"2022042215221959900_B48","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.thromres.2005.11.006","article-title":"Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene","volume":"118","author":"Ishiwata","year":"2006","journal-title":"Thromb Res."},{"issue":"2","key":"2022042215221959900_B49","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1160\/TH04-02-0068","article-title":"Expression of therapeutic levels of factor VIII in hemophilia A mice using a novel adeno\/adeno-associated hybrid virus","volume":"92","author":"Gnatenko","year":"2004","journal-title":"Thromb Haemost."},{"issue":"12","key":"2022042215221959900_B50","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1182\/blood-2003-01-0222","article-title":"Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII","volume":"102","author":"Scallan","year":"2003","journal-title":"Blood."},{"issue":"6","key":"2022042215221959900_B51","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2003-01-0292","article-title":"Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector","volume":"102","author":"Scallan","year":"2003","journal-title":"Blood."},{"issue":"2","key":"2022042215221959900_B52","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1046\/j.1538-7836.2003.00096.x","article-title":"A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype","volume":"1","author":"Sarkar","year":"2003","journal-title":"J Thromb Haemost."},{"issue":"10","key":"2022042215221959900_B53","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1182\/blood.V97.10.3311","article-title":"Induction of tolerance to human factor VIII in mice","volume":"97","author":"Chao","year":"2001","journal-title":"Blood."},{"issue":"1","key":"2022042215221959900_B54","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/ng0595-119","article-title":"Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A","volume":"10","author":"Bi","year":"1995","journal-title":"Nat Genet."},{"issue":"4","key":"2022042215221959900_B55","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1538-7836.2009.03299.x","article-title":"Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in\u00a0vivo bleeding model","volume":"7","author":"Meeks","year":"2009","journal-title":"J Thromb Haemost."},{"issue":"8","key":"2022042215221959900_B56","doi-asserted-by":"crossref","first-page":"6546","DOI":"10.1074\/jbc.M312451200","article-title":"Identification of porcine coagulation factor VIII domains responsible for high level expression via enhanced secretion","volume":"279","author":"Doering","year":"2004","journal-title":"J Biol Chem."},{"issue":"13","key":"2022042215221959900_B57","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2011-08-367813","article-title":"Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs","volume":"119","author":"Dumont","year":"2012","journal-title":"Blood."},{"issue":"1","key":"2022042215221959900_B58","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.thromres.2014.03.028","article-title":"Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII","volume":"134","author":"Zollner","year":"2014","journal-title":"Thromb Res."},{"issue":"1","key":"2022042215221959900_B59","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2516.2011.02608.x","article-title":"Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice","volume":"18","author":"Elm","year":"2012","journal-title":"Haemophilia."},{"issue":"3","key":"2022042215221959900_B60","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/aps.2015.121","article-title":"Pharmacokinetics and pharmacodynamics of SCT800, a new recombinant FVIII, in hemophilia A mice","volume":"37","author":"Gu","year":"2016","journal-title":"Acta Pharmacol Sin."},{"issue":"5","key":"2022042215221959900_B61","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.gt.3302881","article-title":"Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice","volume":"14","author":"Zhang","year":"2007","journal-title":"Gene Ther."},{"key":"2022042215221959900_B62","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3389\/fimmu.2020.01301","article-title":"T-cell dependent immunogenicity of protein therapeutics pre-clinical assessment and mitigation-updated consensus and review 2020","volume":"11","author":"Jawa","year":"2020","journal-title":"Front Immunol."},{"key":"2022042215221959900_B63","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3389\/fimmu.2020.00494","article-title":"The immune response to the fVIII gene therapy in preclinical models","volume":"11","author":"Patel","year":"2020","journal-title":"Front Immunol."},{"issue":"11","key":"2022042215221959900_B64","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/mt.2011.151","article-title":"AAV8-mediated hepatic gene transfer in infant rhesus monkeys (Macaca mulatta)","volume":"19","author":"Wang","year":"2011","journal-title":"Mol Ther."},{"key":"2022042215221959900_B65","doi-asserted-by":"crossref","first-page":"16079","DOI":"10.1038\/mtm.2016.79","article-title":"Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaques","volume":"3","author":"Greig","year":"2016","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"2","key":"2022042215221959900_B66","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1365-2516.2010.02397.x","article-title":"Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb\/c and C57BL\/6 haemophilia A mice","volume":"17","author":"Qadura","year":"2011","journal-title":"Haemophilia."},{"issue":"1","key":"2022042215221959900_B67","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N Engl J Med."},{"issue":"6","key":"2022042215221959900_B68","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/hae.14391","article-title":"Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A","volume":"27","author":"Pasi","year":"2021","journal-title":"Haemophilia."},{"issue":"21","key":"2022042215221959900_B69","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear factor VIII expression after AAV gene transfer for hemophilia A","volume":"385","author":"George","year":"2021","journal-title":"N Engl J Med."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/8\/2628\/1892960\/advancesadv2021006359.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/8\/2628\/1892960\/advancesadv2021006359.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T15:24:20Z","timestamp":1650641060000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/8\/2628\/484390\/Pharmacokinetic-analysis-identifies-a-factor-VIII"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":69,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,4,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006359","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,22]]}}}